These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 6193382)

  • 1. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients.
    Mascart-Lemone F; Huygen K; Clumeck N; Brenez D; Bolla K; Duchateau J
    Lancet; 1983 Sep; 2(8352):735-6. PubMed ID: 6193382
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary results on clinical and immunological effects of thymopentin in AIDS.
    Clumeck N; van de Perre P; Mascart-Lemone F; Cran S; Bolla K; Duchateau J
    Int J Clin Pharmacol Res; 1984; 4(6):459-63. PubMed ID: 6398315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymopentin treatment in AIDS and pre-AIDS patients.
    Clumeck N; Cran S; Van de Perre P; Mascart-Lemone F; Duchateau J; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():58-62. PubMed ID: 3898293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunomodulation in infection caused by human immunodeficiency virus.
    Phair JP
    J Lab Clin Med; 1989 Feb; 113(2):135-6. PubMed ID: 2644386
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
    Levinsky RJ; Davies EG; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):273-6. PubMed ID: 6360239
    [No Abstract]   [Full Text] [Related]  

  • 7. Thymopentin in the treatment of juvenile chronic arthritis.
    Bardare M; Corona F; Ogliari MT; Cohen E
    Clin Exp Rheumatol; 1990; 8(1):89-93. PubMed ID: 1971780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymopentin in the treatment of alopecia areata.
    Orecchia G
    Dermatologica; 1989; 178(4):231. PubMed ID: 2670621
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of thymopentin treatment on the relapse rate in frequently relapsing herpes simplex virus infections.
    Haneke E; Bolla K; Degreef H; Djawari D; Demaubeuge J; Molin L; Panconesi E; Schöpf E; Stengel R; Stingl G
    Int J Clin Pharmacol Res; 1984; 4(6):439-43. PubMed ID: 6085327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of thymopentin in the treatment of post-radiation cystitis].
    Martinoli F; Catania G; Bertana F; Caldera G
    Minerva Urol Nefrol; 1988; 40(4):275-6. PubMed ID: 3075095
    [No Abstract]   [Full Text] [Related]  

  • 11. Thymopoietin pentapeptide treatment of primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Rossi P; Seminara R; Goldstein G
    Lancet; 1983 Mar; 1(8324):551-4. PubMed ID: 6131256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
    Hamilton G; Zöch G; Rath T; Meissl G
    Prog Clin Biol Res; 1989; 308():995-9. PubMed ID: 2528748
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy.
    Barcellini W; Meroni PL; Frasca D; Sguotti C; Borghi MO; Uberti-Foppa C; Buzzetti P; Lazzarin A; Doria G; Moroni M
    Clin Exp Immunol; 1987 Mar; 67(3):537-43. PubMed ID: 3301099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of juvenile rheumatoid arthritis treated with thymopentin].
    Tucciarone L; Felici W; Greco L; Mechelli A
    Minerva Pediatr; 1989 Feb; 41(2):109-11. PubMed ID: 2661988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.
    Franchimont P; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():70-5. PubMed ID: 3898295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymopentin treatment in a patient with pluriorificial pyoderma vegetans.
    Simon M; Djawari D; Horstein OP; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():125-8. PubMed ID: 3898284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymopentin in experimental and clinical medicine.
    Surv Immunol Res; 1985; 4 Suppl 1():1-156. PubMed ID: 3898279
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunostimulation by TP-5 in immunocompromised patients and animals--current status of investigation.
    Waymack JP; Alexander JW
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):225-32. PubMed ID: 3539496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymopentin (TP-5) in the treatment of rheumatoid arthritis.
    Kantharia BK; Goulding NJ; Hall ND; Davies J; Maddison PJ; Bacon PA; Farr M; Wojtulewski JA; Englehart KM; Liyanage SP
    Br J Rheumatol; 1989 Apr; 28(2):118-23. PubMed ID: 2650797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.